# Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC

> **NCT05055167** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 20 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage IV

## Interventions

- **DRUG:** Envafolimab

## Key facts

- **NCT ID:** NCT05055167
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-30
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055167, "Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05055167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*